Document Detail

Treatment of intra-abdominal and abdominal wall desmoid tumors with drugs that affect the metabolism of cyclic 3',5'-adenosine monophosphate.
MedLine Citation:
PMID:  165790     Owner:  NLM     Status:  MEDLINE    
A female patient with Gardner's syndrome was treated with delta1-testololactone (200 mg daily) because of growth of a large desmoid tumor in the pelvis and lower abdomen and a tumor in a scar from a previous laparotomy. There was also pain and swelling of the left leg. An immediate effect of the drug therapy was complete relief of pain followed shortly thereafter by disappearance of the edema of the leg. After two months, the numerous sebaceous cysts were less prominent. The gross measurements of the diameter of the pelvic and lower abdominal tumor clearly demonstrated tumor shrinkage following therapy. Small polyps scattered over the rectal mucosa and numerous osteomata were not demonstrably affected. After one year of treatment with delta1-testololactone, a laparotomy for partial small bowel obstruction was necessary. Obstruction was caused by the involvement of small bowel mesentery and the bowel itself in a contracted residuum of dense fibrous tissue. Substitution of theophylline and chlorothiazide for the testololactone in Januray 1974 was followed by further diminution of the measurable abdominal and pelvic desmoids. All of these compounds synergize the action of 3',5'-adenosine monophosphate and at least the latter two may function by inhibiting the action of 3',5'-adenosine monophosphate diesterase.
W R Waddell
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Annals of surgery     Volume:  181     ISSN:  0003-4932     ISO Abbreviation:  Ann. Surg.     Publication Date:  1975 Mar 
Date Detail:
Created Date:  1975-08-07     Completed Date:  1975-08-07     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0372354     Medline TA:  Ann Surg     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  299-302     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abdominal Muscles* / pathology
Abdominal Neoplasms / drug therapy*
Bone Neoplasms / drug therapy
Cyclic AMP / metabolism*
Fibroma / drug therapy*
Intestinal Polyps / drug therapy
Neoplasms, Multiple Primary / drug therapy
Odontogenic Tumors / drug therapy
Osteoma / drug therapy
Pelvic Neoplasms / drug therapy
Phosphodiesterase Inhibitors
Skin Neoplasms / drug therapy
Testolactone / administration & dosage,  adverse effects,  therapeutic use*
Time Factors
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; 60-92-4/Cyclic AMP; 968-93-4/Testolactone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Factors determining successful liver preservation for transplantation.
Next Document:  Cancer of the bile ducts associated with ulcerative colitis.